Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi offer suggests value in Lemtrada, but not much

This article was originally published in Scrip

Executive Summary

Just over a week after Sanofi received a US FDA refuse-to-file letter on 27 August for its multiple sclerosis drug Lemtrada ( 27 August 2012), the company has offered a premium price to buy the Contingency Value Rights associated with its 2011 purchase of Genzyme. This suggests that Sanofi wants to signal strongly to both its own shareholders and to CVR holders that Lemtrada's (alemtuzumab) problems are resolvable. At the same time, the company may be trying to test investors' perceptions of Lemtrada's prospects in MS in order to calculate how to minimise its outlay on the CVRs in the following months and years.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts